Association between functional EGF+61polymorphism and glioma risk by Costa, Bruno Marques et al.
Association between Functional EGF+61Polymorphism
and Glioma Risk
BrunoMarques Costa,1Paulo Ferreira,4 Sandra Costa,1Paulo Canedo,4 Pedro Oliveira,2 Ana Silva,3
Fernando Pardal,3 Gianpaolo Suriano,4 Jose¤ CarlosMachado,4,5
Jose¤ Manuel Lopes,4,5 and RuiManuel Reis1
Abstract Purpose: Epidermal growth factor (EGF) plays a critical role in cancer. A polymorphism in the
EGF gene (EGF+61) may influence its expression and contribute to cancer predisposition and
aggressiveness. In the present study, we aimed to elucidate the role of EGF+61in glioma suscep-
tibility and prognosis.
Experimental Design:Acase-control study involving197 gliomapatients and 570 controlswas
done. Univariate and multivariate logistic regression analyses were used to calculate odds ratio
(OR) and 95% confidence intervals (95% CI). False-positive report probability was also
assessed.The luciferase reporter gene assay was used to ascertain the functional consequences
of this polymorphism.
Results: Corroborating the univariate analysis, the multivariate model showed that the G allele
conferred higher risks for gliomas (OR,1.32; 95% CI,1.04-1.67), glioblastomas (OR,1.47; 95% CI,
1.02-2.10), andoligodendrogliomas (OR,1.55; 95%CI,1.07-2.23).The GG genotypes were asso-
ciatedwith increased risk for gliomas (OR,1.71; 95%CI,1.07-2.73), glioblastomas (OR, 2.03; 95%
CI, 1.02-4.05), and oligodendrogliomas (OR, 2.72; 95% CI, 1.18-6.28). In addition, the AG+GG
genotypes were associated with higher risk for gliomas (OR,1.52; 95% CI,1.03-2.23) and oligo-
dendrogliomas (OR, 2.80; 95%CI,1.35-5.79). No significant associationwas observed between
the EGF+61polymorphism and glioblastoma or oligodendroglioma patients’overall survival. The
luciferase reporter gene assay exhibited a significant increased promoter activity for the G variant
compared with the referenceA allele.
Conclusions: These findings support the role of the EGF+61polymorphism as a susceptibility
factor for development of gliomas and show its implication on EGF promoter activity.
Central nervous system tumors represent only 2% of all cancer
deaths; however, these tumors rank second as cause of cancer
death in people below 39 years old (1). In fact, central nervous
system tumor patients have the highest average years of life lost
among all cancer types, with an average of 20.1 years (2).
Gliomas are the most frequent central nervous system tumors,
being astrocytic, oligodendroglial, and mixed gliomas (e.g.,
oligoastrocytic), the major histologic types. According to the
WHO, gliomas can be classified into four grades of malignancy
(3). Despite all advances in neurosurgery and adjuvant
radiotherapy and chemotherapy, glioma patients’ prognosis is
dismal (4). Survival of glioblastoma patients, the most
common and aggressive (WHO grade 4) form of glioma in
adults, is very poor, with median survival times ranging from
f10 months in patients younger than 65 years to 3.5 months
for those older than 65 years (5).
Deregulation of growth signaling pathways constitute a
hallmark of cancer (6). Epidermal growth factor (EGF) encodes
a ligand for the EGF receptor (EGFR). Upon EGFR activation, a
cascade of intracellular signaling pathways is initiated that will
ultimately influence cell proliferation, inhibition of apoptosis,
and differentiation (6–9). Alterations of EGF/EGFR signaling
occur frequently in gliomas by several mechanisms, including
autocrine/paracrine stimulation loops, EGFR gene amplifica-
tion, and activating mutations (e.g., EGFRvIII). These abnor-
malities are associated with glioma growth, invasion, and
malignancy (3, 8, 10). Therefore, EGF plays a key role in the
gliomagenesis (9, 10).
Besides somatic molecular alterations, a growing body of
evidence has been demonstrating that common germ line
polymorphisms may play a role in cancer risk and can influence
tumor progression, prognosis, and therapies response (11–15).
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Shahbazi et al. (16) identified a single-nucleotide polymor-
phism in the 5¶ untranslated region of the EGF gene (an A-to-G
variant found 61 bp downstream of the EGF transcription start
site—EGF+61 polymorphism). In this study, the authors found
that the GG genotype was significantly associated with risk of
malignant melanoma and that cells from individuals with the
AA genotype produced significantly less EGF than cells from
individuals with either the AG or GG genotypes. However, later
independent studies have reported some conflicting results
(17–22). Besides melanomas, Bhowmick et al. (23) showed a
relationship between this functional polymorphism and the
risk and aggressiveness of glioblastomas. By studying 42
American patients, they found that both frequencies of G allele
and GA or GG genotypes were significantly higher in
glioblastoma patients than in healthy individuals. Additionally,
patients with the GA or GG genotype had a significant shorter
progression-free survival than those with the AA genotype (23).
Considering the paramount role of EGF/EGFR signaling in
gliomas and the potential implication of EGF+61 in glioblas-
toma development, we proposed to clarify the significance of
this genetic polymorphism in the glioma susceptibility. We did
a case-control study of 197 glioma patients and 570 cancer-free
controls from Portugal. Associations of EGF+61 genotypes with
tumor risk and patient prognosis were assessed. In addition, the
functional consequences of the EGF+61 genetic variants were
evaluated by luciferase reporter analysis.
Materials andMethods
Study population. In this case-control study, we enrolled 197
patients gliomas, diagnosed at Hospital S. Joa˜o, Porto, and Hospital
S. Marcos, Braga, Portugal. All new consecutive cases of glioma patients,
submitted to craniotomy with available tumor material, were eligible,
which represented f60% of patient seen in the two hospitals during
the period of January 1990 to December 2004. Tumors were classified
according to WHO (3), and clinicopathologic features are summarized
in Table 1. The control group was randomly selected from blood
donors at Hospital S. Marcos, Braga, and it included 570 cancer-free
individuals. All patients and controls were from Northwest Portugal
and of Caucasian ethnic background. The procedures followed in the
present study were in accordance with the institutional ethical stand-
ards. All the samples enrolled in the present study were unlinked and
unidentified from their donors.
Genotyping. Cancer patients’ genomic DNA was extracted from
formalin-fixed, paraffin-embedded tumor tissue, as previously de-
scribed (24). No peripheral blood DNA was available from the majority
of glioma patients. DNA from control individuals was extracted from
leukocytes of blood samples by proteinase K/chloroform/isopropanol
treatment (25). The purified DNA was used to determine the genotypes
for the EGF+61 polymorphism, using PCR-RFLP methods as previously
described (23). Briefly, the EGF region from nucleotide positions -78
to +164 was amplified by PCR, producing a 242-bp fragment. After
restriction of the PCR products with 2 units of AluI (Fermentas) for
16 h at 37jC, 61G alleles were distinguished from 61A alleles by
visualization of a single 193-bp fragment instead of 91 and 102 bp
fragments on a 3% agarose gel stained with ethidium bromide.
Plasmid construction. To study the effect on the promoter activity of
the EGF+61 A-G polymorphism, a 756-bp fragment between nucleo-
tides -552 to +204 containing either the A (wild type) or the variant
allele (G) was initially amplified from genomic DNA (isolated from
subjects homozygous either for the A or G allele) with EGF-specific
primers incorporating MluI and HindIII restriction sites (5¶-ACGCGT-
CATACTGTATCTCTTCATTTGG-3¶ and 5¶-AAGCTTTGGAAGCCAGTAA-
GAAATACC-3¶, respectively). The two purified PCR products were
subcloned into pCR2.1 vector (Invitrogen) to obtain plasmid pCR2.1-
EGF+61A or pCR2.1-EGF+61G. The DNA sequences of inserts were
verified by sequencing using M13 primers (Invitrogen). The two
promoter sequences had no sequence differences other than the +61.
The pCR2.1-EGF plasmids containing +61A or +61G were then digested
withMluI and HindIII overnight at 37jC and subcloned into the pGL3-
Basic vector (Promega Corporation), upstream of the firefly luciferase
reporter gene, to generate pGL3-EGF+61A and pGL3-EGF+61G,
respectively. All constructs were checked by direct sequencing using
GLprimer2 and RVprimer3 (Promega) on an ABI PRISM 3100 Genetic
Analyser sequencer (Applied Biosystems).
Cell culture, transfection, and luciferase assay. U251 glioma cells
(kindly provided by Dr. Joseph Costello, University of California, San
Francisco, San Francisco, CA) and MDA-MB-435 breast carcinoma-
derived cells were grown in 50% DMEM and 50% Ham’s F12 medium
supplemented with 10% fetal bovine serum and 1% of penicillin and
streptomycin (Life Technologies), in a humidified atmosphere at 37jC
with 5% CO2. Transient transfection experiments were done using the
LipofectAMINE reagent (Invitrogen). Briefly, cells were seeded in
DMEM at 5.0  105 per well in six-well plates. Transfections were
done the next day by mixing 1 Ag of the pGL3 construct of interest and
0.5 Ag of the control h-galactosidase–expressing vector, with Lipofect-
AMINE 2000 (Invitrogen; LipofectAMINE/DNA ratio of 3:1) in 6 mL of
serum-free and antibiotic-free Opti-MEM (Invitrogen) medium. Cells
were incubated with 1 mL of the transfection mixture for 16 h at 37jC.
Total cell extracts were prepared after 48 h incubation at 37jC in
DMEM using 1 reporter lysis buffer (Promega), as described in the
manufacturer’s instruction manual. Twenty microliters of cell extract
were mixed with 100 AL of luciferase assay reagent (Promega) to
determine luciferase activity in a 1450 Microbeta luminescence counter
(Wallac). The h-galactosidase activity was measured using 50 AL of cell
extract. The luciferase activity of test plasmids is expressed as fold of
induction of the test plasmid activity, after correction for transfection
efficiency as measured by the h-galactosidase activity. Each assay was
repeated in three independent experiments, including three replicates
for the two constructs.
Statistical analysis. m2 and nonparametric Wilcoxon-Mann Whitney
tests were used to compare the frequency distribution of age, sex, and
EGF+61 genotypes and alleles between cases and controls. Moreover,
the m2 test was used to verify that the observed allele distribution, in the
control group, was in Hardy-Weinberg equilibrium. Odds ratios (OR)
and 95% confidence intervals (95% CI) for the effect of EGF+61
variants on the risk for each glioma type were estimated by univariate
and multivariate logistic regression analyses, adjusted for sex and age as
Table 1. Clinicopathologic features of gliomas and
controls
Groups (WHO grade) No.
cases
Age, y
(mean F SD)
Male/
female
ratio
Controls 570 42.6 F 0.6 0.76
Gliomas (1-4) 197 48.5 F 1.2 1.24
Astrocytoma (1-4) 125 50.2 F 1.5 1.16
Pilocytic astrocytoma (1) 9 25.1 F 2.2 0.8
Diffuse astrocytoma (2) 28 36.6 F 3.1 0.87
Anaplastic astrocytoma (3) 3 41.0 F 8.5 3
Glioblastoma (4) 79 57.0 F 1.3 1.32
Gliosarcoma (4) 6 63.8 F 3.5 0.5
Oligodendroglioma (2-3) 66 46.0 F 2.2 1.36
Oligodendroglioma (2) 33 41.2 F 2.9 1.36
Anaplastic
oligodendroglioma (3)
33 51.0 F 3.0 1.36
Oligoastrocytoma 6
Anaplastic
oligoastrocytoma (3)
6 40.5 F 5.4 2
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a continuous variable. False-positive report probability (FPRP) was
calculated for observed significant associations accordingly to
Wacholder et al (26). Following Wacholder et al.’s recommendation
for rare tumors or initial studies, we have calculated FPRP for a range of
prior probabilities from 10% to 0.1% and used a threshold of
noteworthiness of FPRP V0.5 (26). Patient survival curves were assessed
by the Kaplan-Meier method for glioblastoma and oligodendroglioma;
the log-rank test was used to evaluate the differences. Statistical
differences in luciferase reporter assays were assessed using a Student’s
t test. All statistical tests were two-sided, and significance was
considered for P < 0.05. Data analysis was done using SPSS 14.0
software (SPSS, Inc.).
Results
EGF+61 and risk of glioma. We analyzed 197 glioma
patients and 570 cancer-free control individuals to study
associations between EGF+61 polymorphism and susceptibility
to different types of gliomas. The distribution of EGF+61 allele
frequencies in the control group was in Hardy-Weinberg
equilibrium (P = 0.348). A summary of clinicopathologic
features of the controls and cases is shown in Table 1. The
statistical analysis of age and sex distributions between control
and case groups (gliomas, glioblastomas, and oligodendroglio-
mas) showed significant differences for all classes (P < 0.05).
When assessing the allele frequencies using univariate
analysis (Table 2), we found that the G allele was associated
with higher risk for glioma (OR, 1.31; 95% CI, 1.04-1.65) and
oligodendrogliomas (OR, 1.53; 95% CI, 1.06-2.19). Using AA
genotype as reference, the OR analysis showed that both the
GG and combined AG+GG genotypes were associated with
increased risk for glioma (OR, 1.68; 95% CI, 1.07-2.65 for GG;
OR, 1.52; 95% CI, 1.04-2.22 for AG+GG; Table 2). In
oligodendroglioma cases, the AG, GG, and AG+GG genotypes
were all associated with a higher risk (OR, 2.82; 95% CI, 1.33-
5.96 for AG; OR, 2.64; 95% CI, 1.15-6.06 for GG; OR, 2.76;
95% CI, 1.34-5.70 for AG+GG; Table 2). In addition, we
stratified gliomas in astrocytomas (grades 2 and 3, n = 31). A
protective effect was observed for AG genotype (OR, 0.33; 95%
CI, 0.13-0.82; data not shown).
We further used a multivariate logistic regression model
adjusted for sex and age as a continuous variable (Table 3). The
allelic analysis showed that the G allele was a risk factor for
glioma (OR, 1.32; 95% CI, 1.04-1.67), oligodendroglial tumors
(OR, 1.55; 95% CI, 1.07-2.23), and also glioblastoma (OR,
1.47; 95% CI, 1.02-2.10), when compared with the reference A
variant. Consistent with the results obtained by the univariate
analysis (Table 2), the GG and combined AG+GG genotypes
conferred increased risk for glioma (OR, 1.71; 95% CI, 1.07-
2.73 for GG; OR, 1.52; 95% CI, 1.03-2.23 for AG+GG; Table 3).
In oligodendrogliomas, the AG, GG, and AG+GG genotypes
were all associated with higher risks (OR, 2.83; 95% CI, 1.33-
6.02 for AG; OR, 2.72; 95% CI, 1.18-6.28 for GG; OR, 2.80;
95% CI, 1.35-5.79 for AG+GG; Table 3). The GG genotype
increased byf2-fold the risk for glioblastoma (OR, 2.03; 95%
CI, 1.02-4.05; Table 3) in this logistic regression model,
whereas it failed to reach significance in the univariate analysis.
Table 2. Univariate analysis of association between EGF+61 polymorphism and risk for each glioma group
EGF+61 Control Glioma
(1-4)
OR (95% CI) Glioblastoma
(4)
OR (95% CI) Oligodendroglioma
(2-3)
OR (95% CI)
Genotypes
AA 173 44 — 19 — 9 —
AG 266 97 1.43 (0.96-2.15) 35 1.20 (0.66-2.16) 39 2.82 (1.33-5.96)
GG 131 56 1.68 (1.07-2.65) 25 1.74 (0.92-3.29) 18 2.64 (1.15-6.06)
AG+GG 397 153 1.52 (1.04-2.22) 60 1.38 (0.80-2.38) 57 2.76 (1.34-5.70)
Alleles
A 0.537 0.470 — 0.462 — 0.432 —
G 0.463 0.530 1.31 (1.04-1.65) 0.538 1.35 (0.97-1.88) 0.568 1.53 (1.06-2.19)
NOTE: Bold-faced values indicate significant difference at the 5% level.
Table 3. Multivariate logistic regression analysis of the association between EGF+61 polymorphism and risk
for each glioma group
EGF+61 Control Glioma
(1-4)
OR (95% CI) Glioblastoma
(4)
OR (95% CI) Oligodendroglioma
(2-3)
OR (95% CI)
Genotypes
AA 173 44 — 19 — 9 —
AG 266 97 1.43 (0.94-2.15) 35 1.26 (0.67-2.3) 39 2.83 (1.33-6.02)
GG 131 56 1.71 (1.07-2.73) 25 2.03 (1.02-4.05) 18 2.72 (1.18-6.28)
AG+GG 397 153 1.52 (1.03-2.23) 60 1.50 (0.83-2.69) 57 2.80 (1.35-5.79)
Alleles
A 0.537 0.470 — 0.462 — 0.432 —
G 0.463 0.530 1.32 (1.04-1.67) 0.538 1.47 (1.02-2.10) 0.568 1.55 (1.07-2.23)
NOTE: Bold-faced values indicate significant difference at the 5% level.
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The astrocytoma group (grades 2 and 3, n = 31), showed a
protective effective for the AG genotype (OR, 0.32; 95% CI,
0.13-0.82; data not shown).
The calculation of FPRP showed that all of the above-
mentioned associations remained noteworthy (FPRP V 0.5)
when a prior probability of association of z10% was
considered, and all except two associations (glioblastoma and
oligodendroglioma with GG genotype) remained noteworthy
when a prior probability of association of z5% was considered
(Table 4). Concerning the astrocytoma group (grades 2 and 3),
the only remaining noteworthy association was the AG
genotype when a prior probability of association of z10%
was considered (data not shown).
Survival and prognostic value of EGF+61. In glioblastoma
(n = 44) and oligodendroglial tumors (n = 45) with available
follow-up data, we also investigated the association between
EGF+61 genotypes and overall survival time. Kaplan-Meier
analysis did not show any statistically significant correlation
between this polymorphism and glioblastoma patients’ survival
(P = 0.365). Similarly, no associations were found for
oligodendroglial tumors (P = 0.459).
Functional role for the EGF+61 polymorphism by luciferase
reporter assays. Having shown that the +61G allele of the EGF
gene is associated with increased glioma risk, we sought to
determine whether the EGF+61 A to G genetic variation has
functional consequences. To accomplish this, we constructed
two different pGL3-EGF+61 constructs for the +61A and +61G
alleles (pGL3-EGF+61A and pGL3-EGF+61G, respectively) that
were used to transiently transfect U251 glioma cells and MDA-
MB-435 breast carcinoma-derived cells and assess their
promoter activity. The average transcriptional activity of
pGL3-EGF+61G was 1.65- and 1.53-fold higher than of
pGL3-EGF+61A in U251 and MDA-MB-435 cancer cells,
respectively, and these differences were statistically significant
(P = 0.0020 and P = 0.0099, respectively; Fig. 1).
Discussion
Glioma carcinogenesis is a complex and still poorly
understood process in which environmental and genetic factors
cooperate with each other (27). With the exception of
therapeutic ionizing radiation, no other environmental factors
are clearly associated with brain tumors risk (28–31). Recently,
several studies have focused on the etiologic role of germ line
genetic polymorphisms in glioma development and prognosis
(32). These studies included analysis of genes encoding
proteins involved in DNA repair pathways (e.g., MGMT ,
XRCC7 , and ERCC2 ; refs. 33–35), carcinogen metabolism
(e.g., GST and CYP2D6 ; refs. 36–38), and the EGF gene (23).
In this case-control study, we investigated the association of
the EGF+61 polymorphism with glioma susceptibility and
Table 4. False-positive report probability
EGF+61 OR (95% CI) Power* Reported P Prior probability
0.1 0.05 0.01 0.001
Glioma (1-4)
Genotypes (AA reference)
GG 1.71 (1.07-2.73) 0.744 0.025 0.229 0.386 0.766 0.971
AG+GG 1.52 (1.03-2.23) 0.920 0.032 0.240 0.400 0.776 0.972
Alleles (A reference)
G 1.32 (1.04-1.67) 1.00 0.021 0.157 0.282 0.672 0.954
Glioblastoma (4)
Genotypes (AA reference)
GG 2.03 (1.02-4.05) 0.483 0.045 0.453 0.636 0.901 0.989
Alleles (A reference)
G 1.47 (1.02-2.10) 0.995 0.034 0.244 0.405 0.780 0.973
Oligodendroglioma (2-3)
Genotypes (AA reference)
AG 2.83 (1.33-6.02) 0.184 0.007 0.253 0.417 0.788 0.974
GG 2.72 (1.18-6.28) 0.236 0.019 0.422 0.606 0.889 0.988
AG+GG 2.80 (1.35-5.79) 0.182 0.005 0.213 0.364 0.749 0.968
Alleles (A reference)
G 1.55 (1.07-2.23) 0.915 0.018 0.152 0.274 0.663 0.952
NOTE: Bold-faced values indicate the FPRP (V0.5) for the most likely prior probability.
*Estimation of statistical power to detect an OR of 2.0 with an a level equal to the observed P value.
Fig. 1. Relative luciferase activity of human cancer cell lines U251 (glioma) and
MDA-MB-435 (breast carcinoma) transiently transfected with a portion of the EGF
promoter and 5¶-untranslated region, harboring eitherA or G allele at the +61locus.
The results are representative of three independent experiments, including three
replicates for both constructs. *, statistically significant difference using Student’s
t test (P = 0.0020 for U251cells; P = 0.0099 for MDA-MB-435 cells).
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patient prognosis in a large panel of Portuguese cases. It is well
established that the distinct glioma subtypes arise from different
genetic pathways (3, 39, 40); therefore, we have done a
histologic stratification to elucidate more precisely the signifi-
cance of the results. We found a significant association of the G
variant with an increased risk of not only gliomas (OR, 1.35)
but also glioblastomas (OR, 1.48) and oligodendroglial tumors
(OR, 1.58). Notably, we showed that individuals with EGF+61
GG genotype have approximately a 2-fold increased risk for
glioma and glioblastoma and approximately a 3-fold risk for
oligodendroglial tumors. Our data is in agreement with a
previous study reporting a significant association between the
G allele and the risk of developing glioblastoma (23). The
observed OR is likely to reflect a true association, as shown by
the FPRP calculation. Bhowmick et al. (23) have observed a
statistical association between the EGF+61 polymorphism and
glioblastoma patients’ progression-free survival. In the present
series, no statistical association was found between the EGF+61
polymorphisms and glioblastoma and oligodendroglioma
patients overall survival time. In the astrocytoma group (grades
2 and 3), we observed a protective effect associated with the AG
genotype. This paradoxical association is most probably related
to the rather small number of samples (n = 31) analyzed;
however, supplementary studies are warranted to address this
particular subtype of gliomas.
In the present work, the genotype analysis was evaluated in
patient tumor tissue. Thus, we cannot exclude the existence of
somatic alterations in the EGF locus (4q25), which would lead
to misgenotyping. However, chromosomal abnormalities of the
4p25 region are infrequent in gliomas (3). Moreover, in 20
glioma cases with available peripheral blood DNA, genotyping
of both blood and tissue DNA was done with 100%
concordance.
To clarify the biological consequences of this A to G
polymorphism, we used a luciferase reporter gene assay in
glial and breast tumor cells. In both tumor cell types, the
activity of the EGF promoter containing the G allele was >1.5-
fold higher than that of the A variant (reference). These results
corroborate previous studies that reported higher levels of EGF
mRNA expression and protein production by immunoassays
associated with the presence of variant G (16, 23). The
association between the EGF+61 G allele and the increased
production of EGF can have implications not only in
gliomagenesis, as shown in this study, but also for patient
response to the newly developed anti-EGFR therapies (41). In
fact, Zhang et al. (15) have recently reported a pilot study of
molecular markers predictive of clinical outcome in metastatic
colorectal patients treated with the single-agent cetuximab
(anti-EGFR monoclonal antibody). Of the several genetic
polymorphisms evaluated, only the combination of cyclin D1
(A870G) and EGF+61 polymorphisms was associated with
patient survival (41).
In conclusion, we have shown that the EGF+61 polymor-
phism is associated with an increased risk for gliomas,
glioblastomas, and oligodendroglial tumors. In addition, using
luciferase reporter assays, we showed the functional conse-
quences attributable to this polymorphism in glioma and
breast cancer cell lines. In the future, more studies are required
to confirm our results and assess the potential of the EGF+61
polymorphism as a predictor of glioma patients’ outcome and
therapeutic responses to the newly approved anti-EGFR
therapies (42).
Acknowledgments
We thank Dr. J. Costello for kindly providing the glioma tumor cell line.
EGF+61Polymorphism and Risk of Glioma
www.aacrjournals.org Clin Cancer Res 2007;13(9) May1, 20072625
References
1. Jemal A, Murray T,Ward E, et al. Cancer statistics,
2005. CACancerJClin 2005;55:10^30.
2. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP,
Treasure FP. Years of life lost (YLL) from cancer is an
important measure of population burdenAand should
be considered when allocating research funds. Br J
Cancer 2005;92:241^5.
3. Kleihues P, CavaneeWK. Pathology and genetics of
tumours of the nervous system. 2nd ed. Lyon: IARC
Press; 2000.
4. Butowski NA, Sneed PK, Chang SM. Diagnosis and
treatment of recurrent high-grade astrocytoma. J Clin
Oncol 2006;24:1273^80.
5. Davis FG, Freels S, GrutschJ, Barlas S, Brem S. Sur-
vival rates in patients with primary malignant brain
tumors stratified by patient age and tumor histological
type: an analysis based on Surveillance, Epidemiolo-
gy, and EndResults (SEER) data,1973-1991. JNeuro-
surg1998;88:1^10.
6. Hanahan D,Weinberg RA. The hallmarks of cancer.
Cell 2000;100:57^70.
7. Xian CJ, Zhou XF. EGF family of growth factors: es-
sential roles and functional redundancy in the nerve
system. Front Biosci 2004;9:85^92.
8. ZhuY, Parada LF. The molecular and genetic basis of
neurological tumours. Nat Rev Cancer 2002;2:616^26.
9. Salomon DS, Brandt R, Ciardiello F, Normanno N.
Epidermal growth factor-related peptides and their
receptors in human malignancies. Crit Rev Oncol
Hematol 1995;19:183^232.
10. Ekstrand AJ, James CD, CaveneeWK, Seliger B,
Pettersson RF, CollinsVP. Genes for epidermal growth
factor receptor, transforming growth factor a, and epi-
dermal growth factor and their expression in human
gliomas in vivo. Cancer Res1991;51:2164^72.
11. Hunter KW, Crawford NP. Germ line polymorphism
in metastatic progression. Cancer Res 2006;66:
1251^4.
12. Loktionov A. Common gene polymorphisms, can-
cer progression and prognosis. Cancer Lett 2004;
208:1^33.
13. Ulrich CM, Robien K, McLeod HL. Cancer pharma-
cogenetics: polymorphisms, pathways and beyond.
Nat Rev Cancer 2003;3:912^20.
14. Nagasubramanian R, Innocenti F, Ratain MJ. Phar-
macogenetics in cancer treatment. Annu Rev Med
2003;54:437^52. Epub 2001Dec 3.
15. ZhangW, Gordon M, Press OA, et al. Cyclin D1and
epidermal growth factor polymorphisms associated
with survival in patients with advanced colorectal
cancer treated with Cetuximab. Pharmacogenomics
2006;16:475^83.
16. Shahbazi M, PravicaV, Nasreen N, et al. Association
between functional polymorphism in EGF gene and
malignant melanoma. Lancet 2002;359:397^401.
17. McCarron SL, Bateman AC, Theaker JM, Howell
WM. EGF +61gene polymorphism and susceptibility
to and prognostic markers in cutaneous malignant
melanoma. Int JCancer 2003;107:673^5.
18. Amend KL, Elder JT, Tomsho LP, et al. EGF gene
polymorphism and the risk of incident primary mela-
noma. Cancer Res 2004;64:2668^72.
19. Randerson-MoorJA, Gaut R,Turner F, et al. The re-
lationship between the epidermal growth factor (EGF)
5¶UTR variant A61Gandmelanoma/nevus susceptibil-
ity. J Invest Dermatol 2004;123:755^9.
20. Howell WM. Epidermal growth factor gene poly-
morphism and development of cutaneous melanoma.
J Invest Dermatol 2004;123:xx ^ xxi.
21. James MR, Hayward NK, Dumenil T, Montgomery
GW, Martin NG, Duffy DL. Epidermal growth factor
gene (EGF) polymorphism and risk of melanocytic
neoplasia. J Invest Dermatol 2004;123:760^2.
22. Okamoto I, Roka F, Krogler J, et al. The EGF A61G
polymorphism is associated with disease-free period
and survival inmalignant melanoma. JInvestDermatol
2006;126:2242^6.
23. Bhowmick DA, Zhuang Z, Wait SD, Weil RJ. A
functional polymorphism in the EGF gene is found
with increased frequency in glioblastoma multiforme
patients and is associated with more aggressive dis-
ease. Cancer Res 2004;64:1220^3.
24. Basto D,TroviscoV, Lopes JM, et al. Mutation anal-
ysis of B-RAF gene in human gliomas. Acta Neuropa-
thol (Berl) 2005;109:207^10.
25. Mullenbach R, Lagoda PJ,Welter C. An efficient
salt-chloroform extraction of DNA from blood and tis-
sues.Trends Genet 1989;5:391.
26.Wacholder S, Chanock S, Garcia-Closas M, El GL,
Rothman N. Assessing the probability that a posi-
tive report is false: an approach for molecular epi-
demiology studies. J Natl Cancer Inst 2004;96:
434^42.
27. Ohgaki H, Kleihues P. Epidemiology and etiology of
gliomas. Acta Neuropathol (Berl) 2005;109:93^108.
28. Ron E, Modan B, Boice JD, Jr., et al. Tumors of the
brain and nervous system after radiotherapy in child-
hood. NEngl JMed1988;319:1033^9.
29. Neglia JP, Meadows AT, Robison LL, et al. Second
Imaging, Diagnosis, Prognosis
www.aacrjournals.orgClin Cancer Res 2007;13(9) May1, 2007 2626
neoplasms after acute lymphoblastic leukemia in
childhood. NEngl JMed1991;325:1330^6.
30. Relling MV, Rubnitz JE, Rivera GK, et al. High inci-
dence of secondary brain tumours after radiotherapy
and antimetabolites. Lancet1999;354:34^9.
31.Walter AW, Hancock ML, Pui CH, et al. Secondary
brain tumors in children treated for acute lymphoblas-
tic leukemia at St Jude Children’s Research Hospital.
JClin Oncol 1998;16:3761^7.
32.Wrensch M, Fisher JL, Schwartzbaum JA, Bondy
M, Berger M, Aldape KD.The molecular epidemiology
of gliomas in adults. Neurosurg Focus 2005;19:E5.
33.WienckeJK, Aldape K, McMillan A, et al. Molecular
features of adult glioma associated with patient race/
ethnicity, age, and a polymorphism in O6-methylgua-
nine-DNA-methyltransferase. Cancer Epidemiol Bio-
markers Prev 2005;14:1774^83.
34.Wang LE, BondyML, Shen H, et al. Polymorphisms
of DNA repair genes and risk of glioma. Cancer Res
2004;64:5560^3.
35. Caggana M, Kilgallen J, Conroy JM, et al. Asso-
ciations between ERCC2 polymorphisms and glio-
mas. Cancer Epidemiol Biomarkers Prev 2001;10:
355^60.
36. Elexpuru-Camiruaga J, Buxton N, Kandula V, et al.
Susceptibility to astrocytoma and meningioma: influ-
ence of allelism at glutathione S-transferase (GSTT1
and GSTM1) and cytochrome P-450 (CYP2D6) loci.
Cancer Res1995;55:4237^9.
37. Ezer R, Alonso M, Pereira E, et al. Identification of
glutathione S-transferase (GST) polymorphisms in
brain tumors and associationwith susceptibility tope-
diatric astrocytomas. JNeurooncol 2002;59:123^34.
38.Wrensch M, Kelsey KT, Liu M, et al. Glutathione-S-
transferase variants and adult glioma. Cancer Epide-
miol Biomarkers Prev 2004;13:461^7.
39. Louis DN, Holland EC, CairncrossJG. Glioma classi-
fication: a molecular reappraisal. Am J Pathol 2001;
159:779^86.
40. Ohgaki H, Kleihues P. Population-based studies on
incidence, survival rates, and genetic alterations in as-
trocytic and oligodendroglial gliomas. J Neuropathol
Exp Neurol 2005;64:479^89.
41.MendelsohnJ,BaselgaJ.Epidermalgrowthfactorre-
ceptor targeting in cancer. Semin Oncol 2006;33:
369^85.
42. Halatsch ME, Schmidt U, Behnke-Mursch J,
Unterberg A, Wirtz CR. Epidermal growth factor
receptor inhibition for the treatment of glioblas-
toma multiforme and other malignant brain tumours.
CancerTreat Rev 2006;32:74^89.
